GlassScriptPhysician profile
Felipe Galvan
NPI 1841327459
$25,593.67
in general payments reported to CMS, 2019-2025
37 companies · $6,444 in 2025
The $6,444 reported for 2025 was more than what 98% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $3,620 · 2022: $4,834 · 2023: $4,553 · 2024: $6,142 · 2025: $6,444.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $16K · Education: $731.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $16,408.39 |
| Education | $730.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,546.44 | 2021-2025 | |
| Janssen Biotech, INC. | $2,716.79 | 2021-2025 | Tremfya |
| Incyte Corporation | $2,011.01 | 2021-2025 | Opzelura |
| Galderma Laboratories, L.P. | $1,961.72 | 2021-2025 | Nemluvio, Aklief, Twyneo |
| Ucb, INC. | $1,616.08 | 2021-2025 | Bimzelx, Cimzia |
| E.R. Squibb & Sons, L.L.C. | $1,419.76 | 2022-2025 | Sotyktu |
| Lilly USA, LLC | $1,291.69 | 2021-2025 | Taltz, Olumiant, Ebglyss |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $1,291.56 | 2021-2025 | Jublia, Siliq, Cabtreo |
| Regeneron Healthcare Solutions, INC. | $1,014.36 | 2021-2025 | Dupixent, Libtayo |
| Dermavant Sciences, INC. | $1,004.55 | 2022-2024 | Vtama |
| Genzyme Corporation | $950.26 | 2021-2025 | |
| Pfizer INC. | $843.15 | 2021-2025 | |
| Sun Pharmaceutical Industries INC. | $802.33 | 2021-2025 | Ilumya, Winlevi, Absorica Ld |
| Amgen INC. | $781.27 | 2021-2025 | Otezla, Otezla |
| Janssen Scientific Affairs, LLC | $753.80 | 2021-2025 | Tremfya |
Show all 37 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $622.77 | 2023-2025 | Zoryve |
| Novartis Pharmaceuticals Corporation | $499.26 | 2021-2025 | |
| Leo Pharma INC. | $375.50 | 2021-2025 | Adbry, Anzupgo |
| Biofrontera INC. | $346.38 | 2021-2025 | Ameluz, Xepi, Bf-Rhodoled |
| Journey Medical Corporation | $336.08 | 2021-2024 | |
| Revance Therapeutics, INC. | $203.28 | 2024-2025 | Daxxify |
| Mayne Pharma Commercial LLC | $169.09 | 2022-2025 | |
| Sanofi-Aventis U.S. LLC | $157.00 | 2023-2025 | |
| Organon LLC | $153.83 | 2025 | Vtama, Nexplanon |
| Vyne Pharmaceuticals INC. | $140.57 | 2021 | |
| Genentech USA, INC. | $120.65 | 2021-2024 | Xolair |
| Organogenesis INC. | $96.62 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $74.91 | 2023-2024 | Spevigo |
| Teleflex LLC | $51.22 | 2021 | |
| Medimetriks Pharmaceuticals, INC. | $48.65 | 2023-2025 | Clindacin Etz |
| Verrica Pharmaceuticals INC. | $39.53 | 2023 | Ycanth |
| Botanix Sb INC | $32.27 | 2025 | Sofdra |
| Tactile Systems Technology INC | $30.21 | 2022-2024 | Flexitouch Plus, Entre Plus |
| Epi Health, LLC | $29.05 | 2022 | |
| Almirall LLC | $26.60 | 2024 | Seysara |
| Paratek Pharmaceuticals, INC. | $19.96 | 2022 | |
| Kyowa Kirin, INC. | $15.47 | 2024 | Poteligeo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Felipe Galvan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.